Cisco Systems, Inc. (NASDAQ: CSCO) reports its quarterly and fiscal year earnings on Tuesday. First Call is looking for $0.35 EPS and $9.29 billion revenues. Next quarter estimates are $0.36 EPS and $9.38 billion in revenues. We may get fiscal July-2008 targets, and estimates are $1.55 earnings per share (EPS) and $39.7 billion in revenues, so 2008 expectations are an implied 16.5% gain in EPS and a 14% gain in revenues.
Cisco's shares have held up quite well outside of today, with shares trying to remain above $30.00. But the challenge of the $30.00 stock hurdle goes back to January 2004. Now it has Scientific-Atlanta, Webex, and others under its umbrella. In fiscal 2004 the networking giant posted $22.04 billion in revenues and it is expected to have roughly $34.75 billion for this fiscal year (and estimated at $39.7 billion for 2008). The company has also been retiring stock in a big way, even though this last buyback announcement right before earnings seems odd timing.
The average analyst price target is now around $32.00 to $33.00. Back in January, we ran some forward valuations and the scenario that could give Cisco shares a $34.00 stock price mid-year. It is not fair to use options pricing as an estimate several days ahead of the event with erosion of time value and harder in a volatile market, but as of today it appears that options traders are prepared for the stock to move up to 3% in either direction. Cisco was also one of Jim Cramer's TOP PICKS FOR 2007.
Here is a May 8 preview I gave if you want to see any comparisons to then. Shares ended the last quarter under $27.00, so the stock is up about 11% since then ahead of today's sale.
Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.
Last updated: February 12, 2012: 05:19 PM
Hot Stocks
DailyFinance Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
Benzinga Headlines
- Michigan Consumer Sentiment Index Drops
- Don't Bank on Barclays
- GSV Capital Punished for Expanding Facebook Investment
- Chesapeake Gently Lets Go of Gas
- How to Profit off Addicts
TheFlyOnTheWall.com Headlines
- Xstrata shareholders want Glencore offer above three shares, Telegraph says
- France Telecom pursuing greater interest in Egypt's Mobinil, Bloomberg says
- Arab league to ask U.N. for a peacekeeping force in Syria, WSJ says
- Apple asks for preliminary injunction of Samsung Galaxy Nexus, AppleInsider says
- Some walnut growers want to stop selling to Diamond, Reuters says
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Tax Reform in This Election Year: It's Not Likely
Walmart's New Health Food Push: Is It Too Hard to Swallow?

